http://dx.doi.org/10.2147/DDDT.S63235">
 

Document Type

Journal Article

Department/Unit

School of Chinese Medicine

Title

Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro

Language

English

Abstract

Targeted drug delivery to cancer cells by use of antibody-conjugated liposomes (immunoliposomes) has attracted considerable interest in recent years. Despite increasing efforts in developing immunoliposomes as drug carriers, the investigation of useful tumor-associated antigen targets is far from complete. Carbonic anhydrase IX (CA IX) is a cell surface antigen characterized by hypoxia-induced expression in many solid tumors. This study investigated the feasibility of CA IX-directed immunoliposomes for targeted delivery of docetaxel to human lung cancer cells in vitro. Docetaxel-loaded immunoliposomes targeting CA IX were developed with an encapsulation efficiency of 84.4±3.9% and an average particle size of 143.9±11.1 nm. Using fluorescence-based flow cytometry, the in vitro binding activity of the immunoliposomes was found to be significantly higher (by 1.65-fold) than that of the nontargeted liposomes in CA IX-positive lung cancer cells, whereas no such difference was observed between the two groups when CA IX was not expressed. Furthermore, immunoliposomal docetaxel exhibited the strongest growth inhibitory effect against CA IX-positive lung cancer cells when compared with nontargeted liposomal docetaxel or free docetaxel solution. These data suggested that CA IX-directed immunoliposomes could serve as a promising drug delivery system for targeted killing of lung cancer cells. © 2014 Wong et al.

Keywords

Cancer chemotherapy, Cell surface antigen, Conjugation, Hypoxia, Liposome, Nanotechnology

Publication Date

2014

Source Publication Title

Drug Design, Development and Therapy

Volume

8

Start Page

993

End Page

1001

Publisher

Dove Medical Press

ISSN (print)

11778881

ISSN (electronic)

11778881

This document is currently not available here.

Share

COinS